Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 1059Neoplasms 885Prostatic Neoplasms 510Lung Neoplasms 426Colorectal Neoplasms 358Motor Activity 226Uterine Cervical Neoplasms 194Head and Neck Neoplasms 194Carcinoma, Non-Small-Cell Lung 182Brain Neoplasms 174Pancreatic Neoplasms 162Ovarian Neoplasms 143Colonic Neoplasms 140Carcinoma, Hepatocellular 136Anxiety Disorders 125Rectal Neoplasms 119Hematologic Neoplasms 115Multiple Myeloma 109Stomach Neoplasms 105Neoplasm Metastasis 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 97Melanoma 93Depression 93Pain 89Urinary Bladder Neoplasms 88Endometrial Neoplasms 87Glioblastoma 86Disease 85Lymphoma 84Sarcoma 78

Interventions

Dipyrone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Hemostatic Disorders × 1 year × Clear all
NCT07384013 2026-02-03

Study Protocol: Impact of Metamizole (OptalginĀ®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs

Rambam Health Care Campus

Phase NA Recruiting
30 enrolled

Agnosia, Hemostatic Disorders

NCT03826043 2025-09-30

THEO

Centre Antoine Lacassagne

Phase NA Completed
700 enrolled

Neoplasms, Thrombosis, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚔